Abstract
Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.
| Language | English |
|---|---|
| Pages | 107-110 |
| Number of pages | 4 |
| Journal | NeuroReport |
| Volume | 16 |
| Issue number | 2 |
| Publication status | Published - 8 Feb 2005 |
Fingerprint
Keywords
- treatment
- Alzheimer's disease
- dementia
- cholinesterase inhibitors
- disease progression
- donepezil
- neuroimaging
- grey matter
- rivastigmine
- galantamine
- MRI
Cite this
}
Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. / Venneri, A; McGeown, WJ; Shanks, MF.
In: NeuroReport, Vol. 16, No. 2, 08.02.2005, p. 107-110.Research output: Contribution to journal › Article
TY - JOUR
T1 - Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease
AU - Venneri, A
AU - McGeown, WJ
AU - Shanks, MF
PY - 2005/2/8
Y1 - 2005/2/8
N2 - Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.
AB - Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.
KW - treatment
KW - Alzheimer's disease
KW - dementia
KW - cholinesterase inhibitors
KW - disease progression
KW - donepezil
KW - neuroimaging
KW - grey matter
KW - rivastigmine
KW - galantamine
KW - MRI
UR - http://journals.lww.com/neuroreport/Abstract/2005/02080/Empirical_evidence_of_neuroprotection_by_dual.6.aspx
M3 - Article
VL - 16
SP - 107
EP - 110
JO - NeuroReport
T2 - NeuroReport
JF - NeuroReport
SN - 0959-4965
IS - 2
ER -